Search

Your search keyword '"Coldman AJ"' showing total 159 results

Search Constraints

Start Over You searched for: Author "Coldman AJ" Remove constraint Author: "Coldman AJ"
159 results on '"Coldman AJ"'

Search Results

1. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries

2. Erratum to 'The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)' [Gynecol. Oncol. 144 (2017) 405–413](S0090825816314974)(10.1016/j.ygyno.2016.10.019)

3. Erratum to 'The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)' [Gynecol. Oncol. 144 (2017) 405-413]

4. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries

5. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

6. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)

7. Erratum to 'Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)' [Gynecol. Oncol. 144 (2017) 396–404]

8. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

9. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

10. The Canadian Society for Epidemiology and Biostatistics 2016 National Student Conference001INVESTIGATING ECOLOGICAL DETERMINANTS OF MALARIA VECTOR DISTRIBUTION IN RURAL TANZANIA “A MULTI-SCALAR INVESTIGATION”002PREVALENCE AND RISK FACTORS OF TUBERCULOSIS INFECTION AMONG HEALTHCARE TRAINEES IN SOUTH INDIA003SPATIAL MODELLING OF LUNG AND THYROID CANCERS IN UNITED STATES COUNTIES004A MEDIATION ANALYSIS TO ASSESS THE IMPACT OF INHALED CORTICOSTEROIDS (ICSS) DURING PREGNANCY ON BIRTHWEIGHT005MODELLING HUMAN RISK OF WEST NILE VIRUS IN ONTARIO, 2002-2013: INCORPORATING SURVEILLANCE AND ENVIRONMENTAL DATA006EXPLORING THE HEALTH OUTCOMES OF VARIOUS PAN-CANADIAN CERVICAL CANCER SCREENING PROGRAMS USING MICROSIMULATION MODELING007INTEGRATIVE ANALYSIS OF MICRORNA AND GENE EXPRESSION DATA USING SPARSE CANONICAL CORRELATION ANALYSIS008CONDITIONAL DEPENDENCE MODELS UNDER COVARIATE MEASUREMENT ERROR009ASSOCIATION BETWEEN FOOD INSECURITY AND HIV VIRAL SUPPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS010ANTIBIOTICS VERSUS APPENDECTOMY FOR UNCOMPLICATED APPENDICITIS: A GLOBAL HEALTH PERSPECTIVE

11. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies

12. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies

13. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies

14. Breast cancer and hormonal contraceptives: Further results

15. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 95067 women without the disease

16. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries

19. Breast cancer and hormonal contraceptives: further results

21. Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial.

23. Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease

24. The OncoSim-Breast Cancer Microsimulation Model.

25. Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results.

26. Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial.

27. Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening.

28. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.

29. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.

30. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.

31. The OncoSim model: development and use for better decision-making in Canadian cancer control.

32. Post-Loop Electrosurgical Excision Procedure High-Risk Human Papillomavirus Testing as a Test of Cure: The British Columbia Experience.

33. Cancer in First Nations people living in British Columbia, Canada: an analysis of incidence and survival from 1993 to 2010.

34. Aptima HPV Assay versus Hybrid Capture ® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial.

35. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.

36. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.

37. Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval.

38. Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

39. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.

40. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.

41. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.

42. Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada.

43. HAART slows progression to anal cancer in HIV-infected MSM.

44. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.

45. Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program.

46. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.

47. Breast cancer survival and prognosis by screening history.

48. Women's intentions to receive cervical cancer screening with primary human papillomavirus testing.

49. Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort study.

50. Assessing the breast cancer risk distribution for women undergoing screening in British Columbia.

Catalog

Books, media, physical & digital resources